UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

ABCC6

Synonyms: ABC34, ARA, EST349056, MLP1, MOATE, MRP6, PXE, PXE1, URG7

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ	Source	Relative Expression
Brain	Nishimura	`0.0000275`
Kidney*	Nishimura	`0.00873`
Liver*	Nishimura	`0.00982`
Placenta	Nishimura	`0.0000869`
Small Intestine	Nishimura	`0.000960`
Kidney*	Mean across all PMT Samples	`9.933`
Liver*	Mean across all PMT Samples	`66.686`

Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate	Km (μM)	Cell System	Reference
Cisplatin	ND	MRP6-expressing CHO vesicles	Belinsky, 2002
Daunorubicin	ND	MRP6-expressing CHO vesicles	Belinsky, 2002
Leukotriene C4	0.6	MRP6-expressing Sf9 vesicles	Ilias, 2002
N-ethylmaleimide S-glutathione	282	MRP6-expressing Sf9 vesicles	Ilias, 2002

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022

In Vitro Inhibitors

Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
Benzbromarone	ND	N-ethylmaleimide S-glutathione	MRP6-expressing Sf9 vesicles	Ilias, 2002
Indomethacin	ND	N-ethylmaleimide S-glutathione	MRP6-expressing Sf9 vesicles	Ilias, 2002
Probenecid	ND	N-ethylmaleimide S-glutathione	MRP6-expressing Sf9 vesicles	Ilias, 2002

Clinical Drug-Drug Interactions

DDI	Implicated Transporter	Interacting Drug	Affected Drug	AUC	Cmax	CLR	CL/F	t1/2	Effect on PD	Reference	More Details
DDI	Implicated Transporter	Interacting Drug	Affected Drug	Clinical PK Impact(fold change)					Effect on PD	Reference	More Details
1	MRPs	Probenecid	Cefmetazole	1.6	NS	0.6	0.6	1.5	ND	Ko, 1989	DDI 1
2	OATs/MRPs	Probenecid	Ciprofloxacin	1.7	NS	0.4	0.6	1.5	ND	Jaehde, 1995	DDI 2
3	OATs/MRPs	Probenecid	Furosemide	2.7	1.5	0.3	0.4	1.7	ND	Vree, 1995	DDI 3

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022